Src Family Kinases as Therapeutic Targets in Advanced Solid Tumors: What We Have Learned So Far
Open accessThe DOI matches its Crossref record; 176 of the 176 references it cites were found in a registry or an index.
Abstract
Src is the prototypal member of Src Family tyrosine Kinases (SFKs), a large non-receptor kinase class that controls multiple signaling pathways in animal cells. SFKs activation is necessary for the mitogenic signal from many growth factors, but also for the acquisition of migratory and invasive phenotype. Indeed, oncogenic activation of SFKs has been demonstrated to play an important role in solid cancers; promoting tumor growth and formation of distant metastases. Several drugs targeting SFKs have been developed and tested in preclinical models and many of them have successfully reached clinical use in hematologic cancers. Although in solid tumors SFKs inhibitors have consistently confirmed their ability in blocking cancer cell progression in several experimental models; their utilization in clinical trials has unveiled unexpected complications against an effective utilization in patients. In this review, we summarize basic molecular mechanisms involving SFKs in cancer spreading and metastasization; and discuss preclinical and clinical data highlighting the main challenges for their future application as therapeutic targets in solid cancer progression
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to MAPK, SRC kinases can directly modulate many downstream targets including and c-MYC [19, 21, 22, 44], related to drug resistance and tumor cell survival.”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [19]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“SRC kinase, a cytoplasmic non-receptor tyrosine kinase, has been implicated in the development and progression of cancer [19–22].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tissue-based map of the human proteome
Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015) · Science · doi:10.1126/science.1260419 · Cited by 15,286
A pathology atlas of the human cancer transcriptome
Uhlen, M., Zhang, C., Lee, S., Sjöstedt, E., Fagerberg, L., Bidkhori, G., Benfeitas, R., Arif, M., Liu, Z., Edfors, F., et al. (2017) · Science · doi:10.1126/science.aan2507 · Cited by 3,371
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351 · cited 1×
“Drugs able to target Src were predicted in vitro to have a significant inhibitory effect on osteoclast activity [113].”
Lombardo, L. J., Lee, F. Y., Chen, P., Norris, D., Barrish, J. C., Behnia, K., Castaneda, S., Cornelius, L. A. M., Das, J., Doweyko, A. M., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049486a · Cited by 1,297
A SARCOMA OF THE FOWL TRANSMISSIBLE BY AN AGENT SEPARABLE FROM THE TUMOR CELLS
Rous, P. (1911) · Journal of Experimental Medicine · doi:10.1084/jem.13.4.397 · Cited by 1,051 · cited 1×
“Since the original identification of a transmissible agent responsible for the development of solid tumors in chickens, now known to be a retrovirus encoding the v-SRC, significant progress has been made in defining the functions of its human homolog, Src [44].”
Micalizzi, D. S., Farabaugh, S. M., & Ford, H. L. (2010) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-010-9178-9 · Cited by 984 · cited 1×
“Similar results were obtained also in other tumors including prostate and renal cancer [62].”
Role of Src expression and activation in human cancer
Irby, R. B., & Yeatman, T. J. (2000) · Oncogene · doi:10.1038/sj.onc.1203912 · Cited by 857 · cited 1×
“The relationship between Src activation and cancer invasion, the most advanced phase of solid tumor progression, appears to be significant in a wide number of preclinical human cancer models, thus prompting the optimistic use of SFK inhibitors in clinical trials [45].”
Src family kinases in tumor progression and metastasis
Summy, J. M., & Gallick, G. E. (2003) · Cancer and Metastasis Reviews · doi:10.1023/a:1023772912750 · Cited by 827 · cited 2×
“To date, most evidence suggests that Src has a predominant role in the maintenance of the invasive phenotype, rather than of the cell cycle progression [23].”
Structure and regulation of Src family kinases
Boggon, T. J., & Eck, M. J. (2004) · Oncogene · doi:10.1038/sj.onc.1208081 · Cited by 712 · cited 1×
“The SH2 domain, consisting of about 100 amino acid residues, binds phosphorylated Tyr residues in C-terminal domain in the inactive conformation or, in the active form, on other proteins [30].”
Src kinases as therapeutic targets for cancer
Kim, L. C., Song, L., & Haura, E. B. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.129 · Cited by 700
Molecular mechanisms of invadopodium formation
Yamaguchi, H., Lorenz, M., Kempiak, S., Sarmiento, C., Coniglio, S., Symons, M., Segall, J., Eddy, R., Miki, H., Takenawa, T., et al. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200407076 · Cited by 669
Kmiecik, T. E., & Shalloway, D. (1987) · Cell · doi:10.1016/0092-8674(87)90756-2 · Cited by 623 · cited 1×
“The importance of phosphorylation of Tyr530 in the mechanism of inhibition of Src kinase activity is suggested by experimental evidence in which knockout mutant shows a constitutive basal activity associated with oncogenic transformation [35].”
Artym, V. V., Zhang, Y., Seillier-Moiseiwitsch, F., Yamada, K. M., & Mueller, S. C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2177 · Cited by 617 · cited 1×
“The spatiotemporal phosphorylation of cortactin and mAbp1 can regulate invadosome dynamics, with cortactin present at invadopodia during early assembly and stabilization, while mAbp1 is present at mature podosome dots [58,59].”
Differential regulation of cell motility and invasion by FAK
Hsia, D. A., Mitra, S. K., Hauck, C. R., Streblow, D. N., Nelson, J. A., Ilic, D., Huang, S., Li, E., Nemerow, G. R., Leng, J., et al. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200212114 · Cited by 535 · cited 1×
“In fact, phosphorylation of p130Cas by the FAK/Src complex provides a binding site for the SH2 domain of CrkII, which in turn serves as a docking site for Rac1 [49].”
Zhang, S., Huang, W.-C., Li, P., Guo, H., Poh, S.-B., Brady, S. W., Xiong, Y., Tseng, L.-M., Li, S.-H., Ding, Z., et al. (2011) · Nature Medicine · doi:10.1038/nm.2309 · Cited by 515 · cited 1×
“Indeed, combining trastuzumab with dasatinib has a strong preclinical rationale, as suggested by the key role of Src in trastuzumab resistant cancer cell models [122].”
Clark, E. S., Whigham, A. S., Yarbrough, W. G., & Weaver, A. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3928 · Cited by 480 · cited 1×
“Cortactin is a multi-functional Src substrate that is involved in both the assembly and maturation of invadosomes and is important for invasive cell migration [53,54].”
Ostergaard, H. L., Shackelford, D. A., Hurley, T. R., Johnson, P., Hyman, R., Sefton, B. M., & Trowbridge, I. S. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.22.8959 · Cited by 463 · cited 4×
“In contrast to Lck and Fyn, the Src C-terminal phosphotyrosine does not appear subject to dephosphorylation by CD45 [39].”
InfluentialShp2 Regulates Src Family Kinase Activity and Ras/Erk Activation by Controlling Csk Recruitment
Zhang, S. Q., Yang, W., Kontaridis, M. I., Bivona, T. G., Wen, G., Araki, T., Luo, J., Thompson, J. A., Schraven, B. L., Philips, M. R., et al. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00050-4 · Cited by 447 · cited 1×
“Thus, the activity of SHP-2 can result in the failure to activate the inhibitory control of Csk in membrane-associated complexes containing SFKs [43].”
Selected glimpses into the activation and function of Src kinase
Bjorge, J. D., Jakymiw, A., & Fujita, D. J. (2000) · Oncogene · doi:10.1038/sj.onc.1203923 · Cited by 412 · cited 1×
“The SH3 domain of SFKs permits the association with actin filaments that guide the translocation of SFKs towards the cell periphery where they can interact with other molecular partners allowing two major transduction events: (i) signaling from growth factor receptors, which mainly affects cell growth, (ii) signaling…”
Src Family Tyrosine Kinases and Growth Factor Signaling
Abram, C. L., & Courtneidge, S. A. (2000) · Experimental Cell Research · doi:10.1006/excr.1999.4732 · Cited by 391 · cited 1×
“PTP1B phosphatase, which is upregulated in many human solid tumors as colon, lung, and breast cancer, is responsible for the dephosphorylation of Tyr530 and subsequent activation of Src and therefore, for increased tumorigenicity [36,37].”
Action of the Src Family Kinase Inhibitor, Dasatinib (BMS-354825), on Human Prostate Cancer Cells
Nam, S., Kim, D., Cheng, J. Q., Zhang, S., Lee, J.-H., Buettner, R., Mirosevich, J., Lee, F. Y., & Jove, R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1731 · Cited by 377
Oser, M., Yamaguchi, H., Mader, C. C., Bravo-Cordero, J. J., Arias, M., Chen, X., DesMarais, V., van Rheenen, J., Koleske, A. J., & Condeelis, J. (2009) · Journal of Cell Biology · doi:10.1083/jcb.200812176 · Cited by 369 · cited 1×
“Cortactin is a multi-functional Src substrate that is involved in both the assembly and maturation of invadosomes and is important for invasive cell migration [53,54].”
The Role of Src in Solid Tumors
Wheeler, D. L., Iida, M., & Dunn, E. F. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0009 · Cited by 346 · cited 1×
“SFKs interact directly with several tyrosine kinase receptors, G-protein-coupled receptors, steroid receptors, signal transducers, and activators of transcription, leading to a diverse array of biological functions from cell survival to metastases [13].”
Korinek, V., Barker, N., Willert, K., Molenaar, M., Roose, J., Wagenaar, G., Markman, M., Lamers, W., Destree, O., & Clevers, H. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.3.1248 · Cited by 325 · cited 1×
“The Wnt family of secreted glycoproteins mediates the proliferation, invasion, and migration of glioma cells through β-arrestin-dependent signaling [83].”
Combined deficiencies of Src, Fyn, and Yes tyrosine kinases in mutant mice.
Stein, P. L., Vogel, H., & Soriano, P. (1994) · Genes & Development · doi:10.1101/gad.8.17.1999 · Cited by 322 · cited 1×
“However, of the 11 SFK members, Src, Fyn, and Yes have been most frequently implicated in tumorigenesis and metastasis formation [5].”
Bjorge, J. D., Pang, A., & Fujita, D. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004852200 · Cited by 316 · cited 1×
“PTP1B phosphatase, which is upregulated in many human solid tumors as colon, lung, and breast cancer, is responsible for the dephosphorylation of Tyr530 and subsequent activation of Src and therefore, for increased tumorigenicity [36,37].”
An integrin αvβ3–c-Src oncogenic unit promotes anchorage-independence and tumor progression
Desgrosellier, J. S., Barnes, L. A., Shields, D. J., Huang, M., Lau, S. K., Prévost, N., Tarin, D., Shattil, S. J., & Cheresh, D. A. (2009) · Nature Medicine · doi:10.1038/nm.2009 · Cited by 293
Positive and negative regulation of T-cell activation through kinases and phosphatases
MUSTELIN, T., & TASKÉN, K. (2003) · Biochemical Journal · doi:10.1042/bj20021637 · Cited by 274 · cited 1×
“Phosphorylation of pTyr530 works in conjunction with dephosphorylation of pTyr419, mediated by proline-enriched tyrosine phosphatase (PEP), in allowing the complete inactivation of SFKs in vivo [31].”
Involvement of pp60c-src with two major signaling pathways in human breast cancer.
Luttrell, D. K., Lee, A., Lansing, T. J., Crosby, R. M., Jung, K. D., Willard, D., Luther, M., Rodriguez, M., Berman, J., & Gilmer, T. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.1.83 · Cited by 271 · cited 6×
“In HER2-negative bone-prevalent metastatic patients partial responses in bone were noted in 23% of patient (25 total), all with HR-positive cancers, in combination with zolendronic acid [116].”
InfluentialThe Role of Tyrosine Phosphorylation of Cortactin in the Locomotion of Endothelial Cells
Huang, C., Liu, J., Haudenschild, C. C., & Zhan, X. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.40.25770 · Cited by 267 · cited 1×
“Src phosphorylates cortactin at three sites, Y421, Y466, and Y482, and cortactin phosphorylation is important for the formation of invadopodia [55].”
Kaplan, K. B., Bibbins, K. B., Swedlow, J. R., Arnaud, M., Morgan, D. O., & Varmus, H. E. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06800.x · Cited by 249 · cited 1×
“Src, the prototype kinase of SFKs, is a 60-kDa protein able to associate with the plasma, perinuclear, and endosomal membrane via a N-terminal anchoring region that includes the SH4 domain, rich in positively charged residues [24].”
Src phosphorylation of cortactin enhances actin assembly
Tehrani, S., Tomasevic, N., Weed, S., Sakowicz, R., & Cooper, J. A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701077104 · Cited by 239 · cited 2×
“During invadosome precursor formation, signaling proteins such as transmembrane growth factor receptors and/or SFKs organize with structural and adaptor proteins including Tks5, Nck1, and cortactin to recruit the Arp2/3 complex and mediate actin polymerization [52].”
Park, S. I., Zhang, J., Phillips, K. A., Araujo, J. C., Najjar, A. M., Volgin, A. Y., Gelovani, J. G., Kim, S.-J., Wang, Z., & Gallick, G. E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2997 · Cited by 233 · cited 1×
“suggested that Lyn is more important than Src in determining prostate cancer cell proliferation in primary tissue, while Src specific inhibition affects primarily cellular migration [101].”
Araujo, J. C., Trudel, G. C., Saad, F., Armstrong, A. J., Yu, E. Y., Bellmunt, J., Wilding, G., McCaffrey, J., Serrano, S. V., Matveev, V. B., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70479-0 · Cited by 231
Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer
Yu, E. Y., Wilding, G., Posadas, E., Gross, M., Culine, S., Massard, C., Morris, M. J., Hudes, G., Calabrò, F., Cheng, S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1691 · Cited by 220 · cited 3×
“II none SD (3 months) = 43% SD (6 months) = 19% (Mainly bone metastases) 100 mg twice daily and 50 mg twice daily 2009 [115]”
Destaing, O., Sanjay, A., Itzstein, C., Horne, W. C., Toomre, D., De Camilli, P., & Baron, R. (2008) · Molecular Biology of the Cell · doi:10.1091/mbc.e07-03-0227 · Cited by 217 · cited 1×
“This phenotype results from the blockade of osteoclast maturation and in particular from the inhibition of actin dynamics and its organization, a phenomenon essential in resorbing bone [21].”
Rak Functions as a Tumor Suppressor by Regulating PTEN Protein Stability and Function
Yim, E.-K., Peng, G., Dai, H., Hu, R., Li, K., Lu, Y., Mills, G. B., Meric-Bernstam, F., Hennessy, B. T., Craven, R. J., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.02.012 · Cited by 209 · cited 1×
“Frk was described as tumor suppressor in different cancers, at least partly by protecting the tumor suppressor Phosphatase and TENsin homolog (PTEN) from degradation [6].”
Trevino, J. G., Summy, J. M., Lesslie, D. P., Parikh, N. U., Hong, D. S., Lee, F. Y., Donato, N. J., Abbruzzese, J. L., Baker, C. H., & Gallick, G. E. (2006) · The American Journal of Pathology · doi:10.2353/ajpath.2006.050570 · Cited by 208 · cited 1×
“When mice were injected subcutaneously with Src-silenced clone or they were treated with dasatinib, in presence of wild-type tumors, tumor size was decreased, and incidence of metastases was significantly reduced compared with controls [93].”
Haura, E. B., Tanvetyanon, T., Chiappori, A., Williams, C., Simon, G., Antonia, S., Gray, J., Litschauer, S., Tetteh, L., Neuger, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4029 · Cited by 194 · cited 1×
“I/II erlotinib PR = 7% 50 mg twice, or 70 mg twice daily, or 140 mg daily 2010 [137]”
Myoui, A., Nishimura, R., Williams, P. J., Hiraga, T., Tamura, D., Michigami, T., Mundy, G. R., & Yoneda, T. (2003) · PubMed · Cited by 174
Src Kinase Activity Is Regulated by the SHP-1 Protein-tyrosine Phosphatase
Somani, A.-K., Bignon, J. S., Mills, G. B., Siminovitch, K. A., & Branch, D. R. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.34.21113 · Cited by 167 · cited 1×
“SHP-1 is primarily present in cells of hematopoietic origin, SHP-2 is ubiquitous and experimental evidence has established that SHP-1 is involved in dephosphorylating and activation of Src [40].”
Phase II Study of Dasatinib in Patients With Advanced Non–Small-Cell Lung Cancer
Johnson, F. M., Bekele, B. N., Feng, L., Wistuba, I., Tang, X. M., Tran, H. T., Erasmus, J. J., Hwang, L.-L., Takebe, N., Blumenschein, G. R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.5474 · Cited by 166 · cited 1×
“II none SD = 21% 100 mg twice daily reduced to 100 mg + 50 mg daily 2010 [138]”
Gucalp, A., Sparano, J. A., Caravelli, J., Santamauro, J., Patil, S., Abbruzzi, A., Pellegrino, C., Bromberg, J., Dang, C., Theodoulou, M., et al. (2011) · Clinical Breast Cancer · doi:10.1016/j.clbc.2011.03.021 · Cited by 159 · cited 1×
“Advanced breast cancer II none No response (ERmetastatic cases) 175 mg daily 2011 [156]”
Chiang, G. G., & Sefton, B. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101219200 · Cited by 157 · cited 1×
“However, SHP-1 and CD45 are also able to dephosphorylate Tyr-394 in the catalytic domain of Lck and to inactivate Lck, but not Src, suggesting that these phosphatases are not involved only in activation of SFKs but also in the modulation of their specificity [41,42].”
miR-140-5p suppresses the proliferation, migration and invasion of gastric cancer by regulating YES1
Fang, Z., Yin, S., Sun, R., Zhang, S., Fu, M., Wu, Y., Zhang, T., Khaliq, J., & Li, Y. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0708-6 · Cited by 157 · cited 1×
“The prognostic relevance of miR-140-5p in gastric cancer was investigated and Yes was identified as a novel target of miR-140-5p in regulating tumor progression; miR-140-5p serves as a potential prognostic factor in patients with gastric cancer, and miR-140-5p-mediated Yes inhibition is a novel mechanism behind the su…”
A phase 2 trial of dasatinib in advanced melanoma
Kluger, H. M., Dudek, A. Z., McCann, C., Ritacco, J., Southard, N., Jilaveanu, L. B., Molinaro, A., & Sznol, M. (2011) · Cancer · doi:10.1002/cncr.25766 · Cited by 151 · cited 2×
“Other data confirmed a higher partial response in Kit+ melanoma as compared to Kit- melanoma; however, these studies failed in confirming an increased activity than other Kit inhibitors [127,128].”
Demetri, G. D., Lo Russo, P., MacPherson, I. R. J., Wang, D., Morgan, J. A., Brunton, V. G., Paliwal, P., Agrawal, S., Voi, M., & Evans, T. R. J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0224 · Cited by 150 · cited 1×
“I none SD = 19% 100 mg, 150 mg, 200 mg daily 2011 [133] I none SD = 16% 35 to 160 mg twice daily 2009 [134]”
Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition
Wilson, C., Nicholes, K., Bustos, D., Lin, E., Song, Q., Stephan, J.-P., Kirkpatrick, D. S., & Settleman, J. (2014) · Oncotarget · doi:10.18632/oncotarget.2397 · Cited by 145 · cited 13×
“Vimentin expression in this study was suggested as a potential biomarker to identify responsive cancer cell populations associated with an EMT phenotype [65].”
InfluentialD'Angelo, S. P., Shoushtari, A. N., Keohan, M. L., Dickson, M. A., Gounder, M. M., Chi, P., Loo, J. K., Gaffney, L., Schneider, L., Patel, Z., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2349 · Cited by 131 · cited 1×
“High-grade and refractory Advanced Sarcoma Ib ipilimumab No response from 70mg to 100 mg or 70 mg twice, daily 2017 [146]”
Kalinsky, K. M., Lee, S., Rubin, K. M., Lawrence, D. P., Iafrarte, A. J., Borger, D. R., Margolin, K. A., Leitão, M. M., Tarhini, A. A., Koon, H. B., et al. (2017) · Cancer · doi:10.1002/cncr.30663 · Cited by 128 · cited 2×
“Other data confirmed a higher partial response in Kit+ melanoma as compared to Kit- melanoma; however, these studies failed in confirming an increased activity than other Kit inhibitors [127,128].”
Gianni, D., Taulet, N., DerMardirossian, C. M., & Bokoch, G. (2010) · Molecular Biology of the Cell · doi:10.1091/mbc.e10-08-0685 · Cited by 124 · cited 1×
“The involvement of Src in invadopodia formation in CRC was also associated with cancer adaptation to redox stress [85,86].”
Endogenous and synthetic inhibitors of the Src-family protein tyrosine kinases
Chong, Y., Ia, K. K., Mulhern, T. D., & Cheng, H. (2005) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2005.07.027 · Cited by 123 · cited 1×
“This indicates that phosphorylation of inhibitory tyrosine and the resulting intramolecular interaction are not sufficient to maintain SFK activity in a complete inhibited status in vivo [32].”
Buettner, R., Mesa, T., Vultur, A., Lee, F., & Jove, R. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0169 · Cited by 123 · cited 1×
“Other authors confirmed in melanoma cells the prominent role of Src in migration and invasion respect to proliferation, showing an effective role in stimulating MMPs release and phosphorylation of Fak and p130CAS [109].”
Targeted Inhibition of Src Kinase with Dasatinib Blocks Thyroid Cancer Growth and Metastasis
Chan, C. M., Jing, X., Pike, L. A., Zhou, Q., Lim, D., Sams, S. B., Lund, G. S., Sharma, V., Haugen, B. R., & Schweppe, R. E. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3359 · Cited by 120 · cited 1×
“The inhibition of metastatic progression appeared dependent on the ability of dasatinib to block the growth in distant sites rather than the cancer cell dissemination, providing a rationale for treatment of patients with advanced disease [79].”
Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma
Brooks, H. D., Glisson, B. S., Bekele, B. N., Ginsberg, L. E., El‐Naggar, A., Culotta, K. S., Takebe, N., Wright, J., Tran, H. T., & Papadimitrakopoulou, V. A. (2011) · Cancer · doi:10.1002/cncr.25769 · Cited by 116 · cited 1×
“II none SD = 17% 100 mg twice daily reduced to 150 mg daily or 50 mg twice daily 2011 [153]”
Chong, Y., Mulhern, T. D., & Cheng, H. (2005) · Growth Factors · doi:10.1080/08977190500178877 · Cited by 115 · cited 1×
“The phosphorylation of Tyr530 is determined by the action of different tyrosine kinases including Csk (C-terminal Src kinase) and Chk (Csk-homologous kinase) [34].”
In silico identification of oncogenic potential of fyn-related kinase in hepatocellular carcinoma
Chen, J.-S., Hung, W.-S., Chan, H.-H., Tsai, S.-J., & Sun, H. S. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts715 · Cited by 115 · cited 1×
“However, other reports of a potential pro-oncogenic function of Frk also exist, such as in studies evaluating the therapeutic potential of SFKs in liver and pancreatic cancer cell lines [7,8].”
N‐WASP and cortactin are involved in invadopodium‐dependent chemotaxis to EGF in breast tumor cells
DesMarais, V., Yamaguchi, H., Oser, M., Soon, L., Mouneimne, G., Sarmiento, C., Eddy, R., & Condeelis, J. (2009) · Cell Motility · doi:10.1002/cm.20361 · Cited by 114 · cited 2×
“During invadosome precursor formation, signaling proteins such as transmembrane growth factor receptors and/or SFKs organize with structural and adaptor proteins including Tks5, Nck1, and cortactin to recruit the Arp2/3 complex and mediate actin polymerization [52].”
Campone, M., Bondarenko, I., Brincat, S., Hotko, Y., Munster, P. N., Chmielowska, E., Fumoleau, P., Ward, R. L., Bardy‐Bouxin, N., Leip, E. P., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr261 · Cited by 114 · cited 1×
“The phase II study in pretreated patients with locally advanced or metastatic breast cancer achieved a stable disease (>24 months) in more than 20% of patients with few partial responses, all in the subset of patients with HR positive disease [169].”
Ding, Q., Stewart, J., Olman, M., Klobe, M. R., & Gladson, C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304685200 · Cited by 108
Schuetze, S. M., Wathen, J. K., Lucas, D. R., Choy, E., Samuels, B. L., Staddon, A. P., Ganjoo, K. N., von Mehren, M., Chow, W. A., Loeb, D. M., et al. (2015) · Cancer · doi:10.1002/cncr.29858 · Cited by 108 · cited 1×
“II none SD (6 months) = 10–12% (leiomyosarcoma, osteosarcoma, undifferentiated pleomorphic sarcoma) 100 mg daily 2016 [147]”
Mayer, E. L., Baurain, J.-F., Sparano, J., Strauss, L., Campone, M., Fumoleau, P., Rugo, H., Awada, A., Sy, O., & Llombart-Cussac, A. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0070 · Cited by 105 · cited 1×
“II none PR = 4% PR = 100% (HER2 + ER+) 100 mg twice daily reduced to 70 mg twice daily 2011 [143]”
Lara, P. N., Longmate, J., Evans, C. P., Quinn, D. I., Twardowski, P. W., Chatta, G. S., Posadas, E. M., Stadler, W. M., & Gandara, D. R. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328325a867 · Cited by 100
Phosphorylation of unique domains of Src family kinases
Amata, I., Maffei, M., & Pons, M. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00181 · Cited by 99 · cited 1×
“In the canonical pathway, Src activation is initiated by dephosphorylation of pTyr530 (in human Src) followed by a conformational change that permits autophosphorylation at Tyr419 with full activation [28].”
Src-mediated regulation of E-cadherin and EMT in pancreatic cancer
Nagathihalli, N. S. (2012) · Frontiers in bioscience · doi:10.2741/4037 · Cited by 96 · cited 1×
“Oncogenic expression of Src in pancreatic tumor cells was also associated with a reduced expression of E-cadherin in favor of vimentin [61].”
Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines
Eustace, A. J., Crown, J., Clynes, M., & O'Donovan, N. (2008) · Journal of Translational Medicine · doi:10.1186/1479-5876-6-53 · Cited by 94 · cited 1×
“Melanoma frequently shows elevated Src kinase activity, and in preclinical studies dasatinib efficiently inhibited melanoma cell migration and invasion [108].”
Daud, A. I., Krishnamurthi, S. S., Saleh, M. N., Gitlitz, B. J., Borad, M. J., Gold, P. J., Chiorean, E. G., Springett, G. M., Abbas, R., Agarwal, S., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2378 · Cited by 92 · cited 1×
“I none SD = 47% (NSCLC) SD = 29% (colorectal) SD = 22% (pancreas cancer) Escalating from 600 mg daily 2012 [168]”
Yu, E. Y., Massard, C., Gross, M. E., Carducci, M. A., Culine, S., Hudes, G., Posadas, E. M., Sternberg, C. N., Wilding, G., Trudel, G. C., et al. (2011) · Urology · doi:10.1016/j.urology.2011.01.006 · Cited by 90 · cited 2×
“II none SD (3 months) = 44% SD (6 months) = 17% 100 mg daily 2011 [124]”
Johnson, M. L., Riely, G. J., Rizvi, N. A., Azzoli, C. G., Kris, M. G., Sima, C. S., Ginsberg, M. S., Pao, W., & Miller, V. A. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182161508 · Cited by 90 · cited 1×
“II erlotinib PR = 0% (EGFR-mutant and acquired resistance to EGFR-Tirosine Kinase Inhibitors) 70 mg twice daily, 100 mg daily 2011 [136]”
Herold, C. I., Chadaram, V., Peterson, B. L., Marcom, P. K., Hopkins, J., Kimmick, G. G., Favaro, J., Hamilton, E., Welch, R. A., Bacus, S., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1071 · Cited by 90 · cited 1×
“Dynamic analysis in metastatic biopsy of pFak, pPaxillin, and pSRC, in breast cancer patients, failed to reveal informative data, also due to technical challenges associated with the quality of metastatic biopsy and IHC analysis [125].”
Src as the link between inflammation and cancer
Liu, S. T., Pham, H., Pandol, S. J., & Ptasznik, A. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2013.00416 · Cited by 87
Src- and confinement-dependent FAK activation causes E-cadherin relaxation and β-catenin activity
Gayrard, C., Bernaudin, C., Déjardin, T., Seiler, C., & Borghi, N. (2018) · The Journal of Cell Biology · doi:10.1083/jcb.201706013 · Cited by 86
Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness
Ito, H., Gardner-Thorpe, J., Zinner, M. J., Ashley, S. W., & Whang, E. E. (2003) · Surgery · doi:10.1067/msy.2003.224 · Cited by 83 · cited 1×
“In fact, also in this tumor model the inhibition of Src was associated with reduced MMPs activity and invasiveness [94].”
Wang, X.-D., Reeves, K., Luo, F. R., Xu, L.-A., Lee, F., Clark, E., & Huang, F. (2007) · Genome Biology · doi:10.1186/gb-2007-8-11-r255 · Cited by 83 · cited 1×
“This latter aspect is exacerbated by the absence of patient stratification, in fact, the Src-mediated pathway can act both in co-operation or cross-talk with other signaling pathways rendering difficult to find the best surrogate marker at a single patient level [118].”
Kim, S., Alsaidan, O., Goodwin, O., Li, Q., Sulejmani, E., Han, Z., Bai, A., Albers, T., Beharry, Z., Zheng, Y., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0981 · Cited by 83
Chakraborty, G., Rangaswami, H., Jain, S., & Kundu, G. C. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512546200 · Cited by 81 · cited 1×
“Indeed, the cross-talk between Syk and Lck regulates hypoxia/reoxygenation, a process modelling breast cancer cell phenotype in advanced stages [69].”
Dwyer, A. R., Greenland, E. L., & Pixley, F. J. (2017) · Cancers · doi:10.3390/cancers9060068 · Cited by 81 · cited 8×
“While the degradation of ECM through Src-induced invadopodia formation seems to be FAK-independent, further studies revealed that TRIB1-mediated migration and invasion of CRC cells required up-regulation of MMP-2 through the activation of FAK/Src and ERK pathway [87].”
InfluentialAngelucci, A., Schenone, S., Gravina, G. L., Muzi, P., Festuccia, C., Vicentini, C., Botta, M., & Bologna, M. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.06.024 · Cited by 79 · cited 3×
“The action of small molecule inhibitors appeared to involve, in parallel with Src inhibition, the down-modulation of the active forms of paxillin and extracellular signal-regulated kinase (ERK) [96].”
Self-citationJe, D. W., Young Moon, O., Ji, Y. G., Cho, Y., & Lee, D. H. (2014) · Pancreas · doi:10.1097/mpa.0000000000000103 · Cited by 77 · cited 2×
“However, other reports of a potential pro-oncogenic function of Frk also exist, such as in studies evaluating the therapeutic potential of SFKs in liver and pancreatic cancer cell lines [7,8].”
Phase II Study of Dasatinib (BMS-354825) in Patients With Metastatic Adenocarcinoma of the Pancreas
Chee, C. E., Krishnamurthi, S., Nock, C. J., Meropol, N. J., Gibbons, J., Fu, P., Bokar, J., Teston, L., O'Brien, T., Gudena, V., et al. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0255 · Cited by 76 · cited 1×
“II none SD = 29% Metastatic cases 100 mg twice daily reduced to 70 mg twice daily 2013 [141]”
Fury, M. G., Baxi, S. S., Shen, R., Kelly, K. W., Lipson, B. L., Carlson, D. L., Stambuk, H. E., Haque, S. S., & Pfister, D. G. (2011) · PubMed · Cited by 75
Wu, J.-C., Chen, Y., Kuo, C.-T., Yu, H. W., Chen, Y., Chiou, A., & Kuo, J. (2015) · Scientific Reports · doi:10.1038/srep18476 · Cited by 75 · cited 2×
“In addition, the association of Src with FAs plays a key role in transducing Src-mediated signals, in the promotion of FA formation/maturation and in enhancing cell migration [25].”
Evans, T. R. J., Cutsem, E. V., Moore, M. J., Bazin, I. S., Rosemurgy, A. S., Bodoky, G., Deplanque, G., Harrison, M., Melichar, B., Pezet, D., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw607 · Cited by 74 · cited 1×
“Advanced pancreatic cancer I Erlotinib gemcitabine SD = 69% 70 mg daily reduced to 50 mg daily 2018 [139] II gemcitabine No response 100 mg daily 2017 [140]”
YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib
Garmendia, I., Pajares, M. J., Hermida‐Prado, F., Ajona, D., Bértolo, C., Sainz, C., Lavín, A., Remírez, A., Valencia, K., Moreno, H., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201807-1292oc · Cited by 73 · cited 1×
“showed that molecular alterations of Yes can be found in a significant subset of patients with lung cancer and they demonstrated an association between these alterations and prognosis using Yes status as predictive biomarker [76].”
Ngan, E., Stoletov, K. V., Smith, H. W., Common, J. L., Muller, W. J., Lewis, J. D., & Siegel, P. M. (2017) · Nature Communications · doi:10.1038/ncomms15059 · Cited by 72 · cited 1×
“Specifically, Src overexpression or overactivation was associated with the aberrant formation of invadopodia, critical morphological structures employed by cancer cells to intravasate into the bloodstream and extravasate into secondary sites during the metastatic process [16,17].”
Yeo, M. G., Oh, H. J., Cho, H., Chun, J. S., Marcantonio, E. E., & Song, W. K. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22335 · Cited by 71 · cited 14×
“Knockdown of Src, Fyn, and Yes significantly reduced migration of LN229 cells on collagen, while Lyn knockdown had no effect.”
InfluentialMicroRNA-mediated upregulation of integrin-linked kinase promotes Src-induced tumor progression
Oneyama, C., Morii, E., Okuzaki, D., Takahashi, Y., Ikeda, J., Wakabayashi, N., Akamatsu, H., Tsujimoto, M., Nishida, T., Aozasa, K., et al. (2011) · Oncogene · doi:10.1038/onc.2011.367 · Cited by 70 · cited 1×
“MiR-542-3p expression is downregulated by the activation of Src-related signaling molecules, including epidermal growth factor receptor, K-Ras, and Ras/Raf/mitogen-activated protein kinase/extracellular signal-regulated kinase [90].”
Schott, A. F., Barlow, W. E., Poznak, C. H. V., Hayes, D. F., Moinpour, C. M., Lew, D. L., Dy, P. A., Keller, E. T., Keller, J. M., & Hortobágyi, G. N. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3911-z · Cited by 70 · cited 3×
“II none PR = 4% (bone metastases) 70 mg twice daily and 100 mg daily 2016 [114]”
InfluentialDevelopment of T‐leukaemias in CD45 tyrosine phosphatase‐deficient mutant lck mice
Baker, M., Gamble, J. A., Tooze, R. M., Higgins, D., Yang, F., O´Brien, P. C. M., Coleman, N., Pingel, S., Turner, M., & Alexander, D. R. (2000) · The EMBO Journal · doi:10.1093/emboj/19.17.4644 · Cited by 69 · cited 1×
“However, SHP-1 and CD45 are also able to dephosphorylate Tyr-394 in the catalytic domain of Lck and to inactivate Lck, but not Src, suggesting that these phosphatases are not involved only in activation of SFKs but also in the modulation of their specificity [41,42].”
Parseghian, C. M., Parikh, N. U., Wu, J. Y., Jiang, Z.-Q., Henderson, L., Tian, F., Pastor, B., Ychou, M., Raghav, K., Dasari, A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3138 · Cited by 67 · cited 1×
“Metastatic colorectal cancer Ib/II FOLFOX chemiotherapy w and w/o cetuximab SD = 47% PR = 20% 100, 150, 200 mg daily 2017 [149]”
The role of Src family kinases in growth and migration of glioma stem cells
Han, X., Zhang, W., Yang, X., Wheeler, C. G., Langford, C. P., Wu, L., Filippova, N., Friedman, G. K., Ding, Q., Fathallah‐Shaykh, H. M., et al. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2432 · Cited by 66 · cited 1×
“For glioma growth and migration on laminin it was described as a role for Fyn, Src, and Yes [80,81].”
A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer
Fornier, M. N., Morris, P. G., Abbruzzi, A., D’Andrea, G. M., Gilewski, T., Bromberg, J., Dang, C. T., Dickler, M. N., Modi, S., Seidman, A. D., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr018 · Cited by 66 · cited 1×
“I paclitaxel PR = 31% SD = 29% 70–120 mg daily 2011 [144]”
Src family kinases differentially influence glioma growth and motility
Lewis‐Tuffin, L. J., Feathers, R. W., Hari, P., Durand, N., Li, Z., Rodríguez, F. J., Bakken, K., Carlson, B. L., Schroeder, M. A., Sarkaria, J. N., et al. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.06.001 · Cited by 66 · cited 1×
“In contrast, when using a different cell line, SF767, in the same experimental conditions only Yes knockdown significantly reduced cancer cell migration [82].”
Okamoto, W., Okamoto, I., Yoshida, T., Okamoto, K., Takezawa, K., Hatashita, E., Yamada, Y., Kuwata, K., Arao, T., Yanagihara, K., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0002 · Cited by 64
Ocaña, A., Gil-Martín, M., Antolín, S., Atienza, M., Montaño, Á., Ribelles, N., Urruticoechea, A., Falcón, A., Pernas, S., Orlando, J., et al. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-05100-z · Cited by 64 · cited 2×
“Advanced breast cancer II trastuzumab paclitaxel PR = 69% SD = 10% (HER2 + metastatic cases) 100 mg daily 2019 [121]”
(1996) · PubMed · Cited by 63
Secord, A. A., Teoh, D. K., Barry, W. T., Yu, M., Broadwater, G., Havrilesky, L. J., Lee, P. S., Berchuck, A., Lancaster, J., & Wenham, R. M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0507 · Cited by 63 · cited 1×
“Advanced ovarian cancer I paclitaxel carboplatin PR = 25% SD = 50% 100, 120, 150 mg daily 2012 [148]”
Liu, X., & Feng, R. (2010) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmq043 · Cited by 62 · cited 1×
“Src inhibition induces in breast cancer cells a reverted epithelial phenotype associated with an increase of E-cadherin and a decrease of vimentin and it blocks cancer cell migration [60].”
Olea‐Flores, M., Zuñiga‐Eulogio, M. D., Tacuba-Saavedra, A., Bueno-Salgado, M., Sánchez-Carvajal, A., Vargas-Santiago, Y., Catalán, M. A. M., Salazar, E. P., García-Hernández, A. P., Padilla‐Benavides, T., et al. (2019) · Cells · doi:10.3390/cells8101133 · Cited by 62 · cited 1×
“Also, leptin, one of the main adipokines secreted in breast tissue, can promote EMT through Src activation, leading to the secretion and activation of cell invasion and tumor progression [67].”
FYN promotes breast cancer progression through epithelial-mesenchymal transition
Xie, Y.-G., Yu, Y., Hou, L.-K., Wang, X., Zhang, B., & Cao, X.-C. (2016) · Oncology Reports · doi:10.3892/or.2016.4894 · Cited by 59 · cited 1×
“Furthermore, Fyn was transcriptionally regulated by FOXO1 and it mediated FGF2-induced EMT through both the PI3K/AKT and ERK/MAPK pathways [68].”
Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer
Morris, P. G., Rota, S., Cadoo, K. A., Zamora, S., Patil, S. N., D’Andrea, G. M., Gilewski, T., Bromberg, J., Dang, C. T., Dickler, M. N., et al. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2018.03.010 · Cited by 59 · cited 1×
“II paclitaxel CR = 3% PR = 20% (mainly ER+) 120 mg daily 2018 [142]”
Dual Mechanisms of LYN Kinase Dysregulation Drive Aggressive Behavior in Breast Cancer Cells
Tornillo, G., Knowlson, C. N., Kendrick, H. D., Cooke, J., Mirza, H., Aurrekoetxea-Rodríguez, I., Vivanco, M. D., Buckley, N. E., Grigoriadis, A. E., & Smalley, M. J. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.103 · Cited by 59 · cited 1×
“Since the involvement of different SFKs in breast cancer, different authors evaluated the effect of specific SFK inhibitors or knockdown of individual SFK members in breast cancer cells and compared the potential effects of pan-SFK and SFK-selective inhibitors on the formation of breast cancer metastasis in preclinica…”
Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma
Gangadhar, T. C., Clark, J. I., Karrison, T. G., & Gajewski, T. F. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9897-4 · Cited by 58 · cited 1×
“Recurrent and metastatic HNSCC II none No response 175 mg daily 2011 [166] Metastatic Clear-Cell Renal Cancer II cediranib PR = 15% 175 mg daily 2016 [163] Metastatic melanoma II none SD = 9% 175 mg daily 2013 [167]”
Brunner, A. M., Costa, D. B., Heist, R. S., Garcia, E. P., Lindeman, N. I., Sholl, L. M., Oxnard, G. R., Johnson, B. E., & Hammerman, P. S. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182a47162 · Cited by 57
Twardowski, P. W., Beumer, J. H., Chen, C. S., Kraft, A. S., Chatta, G. S., Mitsuhashi, M., Ye, W., Christner, S. M., & Lilly, M. B. (2013) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328361feb0 · Cited by 57 · cited 2×
“Metastatic castration resistant prostate cancer II none SD = 19% PR = 4% 70 mg twice reduced to 100 mg daily 2013 [117]”
A Novel Nonreceptor Tyrosine Kinase, Srm: Cloning and Targeted Disruption
Kohmura, N., Yagi, T., Tomooka, Y., Oyanagi, M., Kominami, R., Takeda, N., Chiba, J., Ikawa, Y., & Aizawa, S. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.10.6915 · Cited by 57
Src-mediated regulation of the PI3K pathway in advanced papillary and anaplastic thyroid cancer
Beadnell, T. C., Nassar, K. W., Rose, M. M., Clark, E. G., Danysh, B. P., Hofmann, M.-C. C., Pozdeyev, N. V., & Schweppe, R. E. (2018) · Oncogenesis · doi:10.1038/s41389-017-0015-5 · Cited by 57 · cited 1×
“The combined inhibition of Src and the MAPK pathway holds great promise for improving the overall survival of advanced thyroid cancer patients with Braf and Ras mutations, and activation of the PI3K pathway represents an important biomarker of response for patients treated with this therapy [78].”
MacKay, H. J., Au, H., McWhirter, E., Alcindor, T., Jarvi, A., MacAlpine, K., Wang, L. E., Wright, J. J., & Oza, A. M. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9650-4 · Cited by 56
Gubens, M. A., Burns, M., Perkins, S. M., Pedro-Salcedo, M. S., Althouse, S. K., Loehrer, P. J., & Wakelee, H. A. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.04.008 · Cited by 56 · cited 1×
“Advanced thymic tumors II none SD = 43% 175 mg daily 2015 [164] Advanced gastric or gastro Oesophageal Junction (GEJ) Adenocarcinoma II none SD = 18% 175 mg daily 2012 [165]”
Kim, J., Kim, J. H., Lee, Y., Yang, H. S., Heo, Y.-S., Bode, A. M., Lee, K. W., & Dong, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.7524 · Cited by 56 · cited 4×
“that the EGF-stimulated anchorage-independent growth of A431 human epidermoid carcinoma cells could be inhibited by blocking the kinase activity of Hck and Blk [110].”
InfluentialBauman, J. E., Duvvuri, U., Gooding, W. E., Rath, T. J., Gross, N. D., Song, J. I., Jimeno, A., Yarbrough, W. G., Johnson, F. M., Wang, L., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.90449 · Cited by 56 · cited 2×
“For example, basal expression of pSTAT3 may be independent of Src, explaining therapeutic resistance, and precluding a correct analysis of dasatinib in biomarker-unselected cohorts [119].”
Renouf, D. J., Moore, M. J., Hedley, D. W., Gill, S., Jonker, D. J., Chen, E. X., Walde, D., Goel, R., Southwood, B., Gauthier, I. C., et al. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9611-3 · Cited by 55 · cited 2×
“Advanced pancreatic cancer I/II gemcitabine SD (4 months) = 23% PR = 9% 175 mg daily 2012 [160]”
Sudol, M., Greulich, H. E., Newman, L. S., Sarkar, A., Sukegawa, J., & Yamamoto, T. (1993) · PubMed · Cited by 54
Lyn modulates Claudin-2 expression and is a therapeutic target for breast cancer liver metastasis
Tabariès, S., Annis, M. G., Hsu, B. E., Tam, C., Savage, P., Park, M., & Siegel, P. M. (2015) · Oncotarget · doi:10.18632/oncotarget.3269 · Cited by 53 · cited 1×
“Also, the authors studied the expression of claudin-2, an important positive modulator of breast cancer liver metastasis, showing that the knockdown of individual SFK members, including Yes and Fyn, induced Claudin-2 expression, while contrary to this, Lyn-selective kinase inhibitor, bafetinib (INNO-406), reduced Clau…”
Somlo, G., Atzori, F., Strauss, L. C., Geese, W. J., Specht, J. M., Gradishar, W. J., Rybicki, A., Sy, O., Vahdat, L. T., & Cortes, J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0652 · Cited by 53 · cited 3×
“I capecitabine PR = 24% SD = 32% 50 or 70 mg twice or 100 mg daily 2013 [111]”
Gene Signature–Guided Dasatinib Therapy in Metastatic Breast Cancer
Pusztai, L., Moulder, S. L., Altan, M., Kwiatkowski, D. N., Valero, V., Ueno, N. T., Esteva, F. J., Avritscher, R., Qi, Y., Strauss, L. C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0800 · Cited by 52 · cited 2×
“However, neither complex gene expression analysis of three different gene signatures previously validated in vitro, has permitted to define tumors clinically sensitive to dasatinib as a single agent [112].”
Wang, Y., Wu, N., Pang, B., Tong, D., Sun, D., Sun, H., Zhang, C., Sun, W., Meng, X., Bai, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18201 · Cited by 51 · cited 1×
“While the degradation of ECM through Src-induced invadopodia formation seems to be FAK-independent, further studies revealed that TRIB1-mediated migration and invasion of CRC cells required up-regulation of MMP-2 through the activation of FAK/Src and ERK pathway [87].”
Elevated c-Src and c-Yes expression in malignant skin cancers
Lee, J. H., Pyon, J.-K., Kim, D. W., Lee, S.-H., Nam, H. S., Kim, C. H., Kang, S. G., Lee, Y. J., Park, M. Y., Jeong, D. J., et al. (2010) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-29-116 · Cited by 48 · cited 1×
“Some evidence indicates that Src is expressed in highly aggressive skin tumors, while Yes is expressed more in squamous cancer carcinoma compared to other skin cancers [107].”
Roseweir, A. K., Powell, A. G. M. T., Horstman, S. L., Inthagard, J., Park, J. H., McMillan, D., Horgan, P. G., & Edwards, J. (2019) · Cellular Signalling · doi:10.1016/j.cellsig.2019.01.007 · Cited by 48 · cited 8×
“While the degradation of ECM through Src-induced invadopodia formation seems to be FAK-independent, further studies revealed that TRIB1-mediated migration and invasion of CRC cells required up-regulation of MMP-2 through the activation of FAK/Src and ERK pathway [87].”
InfluentialA Phase I/II Study Combining Erlotinib and Dasatinib for Non-Small Cell Lung Cancer
Gold, K. A., Lee, J. J., Harun, N., Tang, X., Price, J., Kawedia, J. D., Tran, H. T., Erasmus, J. J., Blumenschein, G. R., William, W. N., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0228 · Cited by 46 · cited 2×
“I/II erlotinib PR = 15% (EGFR mutated population) 70 mg daily 2014 [129]”
Mitri, Z. I., Nanda, R., Blackwell, K., Costelloe, C. M., Hood, I., Wei, C., Brewster, A. M., Ibrahim, N. K., Koenig, K. B., Hortobágyi, G. N., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2845 · Cited by 45 · cited 3×
“I/II zolendronic acid CR + PR = 23% SD = 13% From 70 mg twice daily to 100 mg daily 2016 [116]”
InfluentialPosadas, E. M., Ahmed, R. S., Karrison, T. G., Szmulewitz, R. Z., O’Donnell, P. H., Wade, J. L., Shen, J., Gururajan, M., Sievert, M. F., & Stadler, W. M. (2015) · The Prostate · doi:10.1002/pros.23119 · Cited by 44
Mello, A. A., Leal, M. F., REY, J. A., Pinto, G. R., Lamarão, L. M., Montenegro, R. C., Alves, A. P. N. N., de Assumpção, P. P., Borges, B. D. N., Smith, M. D. A. C., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140492 · Cited by 44 · cited 1×
“Src and Lyn kinases were upregulated in half of gastric cancer tissues and they associate with grade and metastases [102].”
Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma
Algazi, A. P., Weber, J. S., Andrews, S., Urbas, P., Münster, P. N., DeConti, R. C., Hwang, J. H., Sondak, V. K., Messina, J. L., McCalmont, T. H., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.514 · Cited by 43 · cited 2×
“I dacarbazine PR+SD = 62% (metastatic cases) 70 mg twice daily 2012 [126]”
Specific Oncogenic Activity of the Src-Family Tyrosine Kinase c-Yes in Colon Carcinoma Cells
Sancier, F., Dumont, A., Sirvent, A., Paquay de Plater, L., Edmonds, T., David, G., Jan, M., de Montrion, C., Cogé, F., Léonce, S., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017237 · Cited by 43 · cited 1×
“Yes silencing also determined a reduction in the capacity to generate liver metastases in vivo [91].”
c-Src activity is differentially required by cancer cell motility modes
Logue, J. S., Cartagena‐Rivera, A. X., & Chadwick, R. S. (2018) · Oncogene · doi:10.1038/s41388-017-0071-5 · Cited by 43
Furlan, G., Minowa, T., Hanagata, N., Kataoka-Hamai, C., & Kaizuka, Y. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.574319 · Cited by 42
Isakoff, S. J., Wang, D., Campone, M., Calles, A., Leip, E. P., Turnbull, K. W., Bardy‐Bouxin, N., Duvillié, L., & Calvo, E. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.508 · Cited by 41 · cited 2×
“Advanced solid tumors I capecitabine SD = 64% (colorectal cancer) SD = 45% (breast cancer) 300 mg daily 2014 [173]”
Stabile, L. P., Egloff, A. M., Gibson, M. K., Gooding, W. E., Ohr, J. P., Zhou, P., Rothenberger, N. J., Wang, L., Geiger, J. L., Flaherty, J. T., et al. (2017) · Oral Oncology · doi:10.1016/j.oraloncology.2017.03.011 · Cited by 40 · cited 1×
“Metastatic Head and Neck Squamous Cell Carcinoma II cetuximab SD = 36% (mainly in low serum IL6) 150 mg daily 2017 [152]”
Paladino, D., Yue, P., Furuya, H., Acoba, J. D., Rosser, C. J., & Turkson, J. (2015) · Oncotarget · doi:10.18632/oncotarget.6635 · Cited by 38 · cited 1×
“Recent studies have reported the presence of Src also in the nuclear compartment, and this localization seems to be relevant in the progression of some solid tumors [26,27].”
Suppression of SRC Signaling Is Effective in Reducing Synergy between Glioblastoma and Stromal Cells
Calgani, A., Vignaroli, G., Zamperini, C., Coniglio, F., Festuccia, C., Cesare, E. D., Gravina, G. L., Mattei, C. D., Vitale, F., Schenone, S., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-1011 · Cited by 38
Self-citationLaurie, S. A., Goss, G. D., Shepherd, F. A., Reaume, M. N., Nicholas, G. A., Philip, L., Wang, L. E., Schwock, J., Hirsh, V., Oza, A. M., et al. (2013) · Clinical Lung Cancer · doi:10.1016/j.cllc.2013.08.001 · Cited by 35 · cited 2×
“Therefore, it was hypothesized, also considering data from dasatinib, that there may be a subpopulation of patients with advanced NSCLC that can benefit from Src inhibition [157].”
Moy, B., Neven, P., Lebrun, F., Bellet, M., Xu, B., Sarosiek, T., Chow, L. W. C., Goss, P. E., Zacharchuk, C., Leip, E. P., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0021 · Cited by 35
Kaye, S. B., Aamdal, S., Jones, R. D., Freyer, G., Pujade-Lauraine, É., de Vries, E. G. E., Barriuso, J., Sandhu, S. K., Tan, D. S. W., Hartog, V., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.158 · Cited by 35 · cited 2×
“Saracatinib was given to most patients with acceptable toxicity in combination with paclitaxel, with the most significant efficacy observed in patient with platinum-resistant ovarian cancer [161].”
Schuetze, S. M., Bolejack, V., Thomas, D. G., von Mehren, M., PATEL, S. R., Samuels, B. L., Choy, E., D’Amato, G. Z., Staddon, A. P., Ganjoo, K. N., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0601 · Cited by 34 · cited 1×
“Imatinib-refractory metastatic Gastrointestinal Stromal Tumors II none PR = 25% (PFS = 50% in pSRC+) 70 mg twice daily 2018 [145]”
Powles, T. B., Brown, J. E., Larkin, J., Jones, R. J., Ralph, C., Hawkins, R. E., Chowdhury, S., Boleti, E., Bhal, A., Fife, K. M., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw014 · Cited by 32
Li, M.-Y., Peng, W.-H., Wu, C., Chang, Y.-M., Lin, Y., Chang, G., Wu, H., & Chen, G. (2019) · Oncogene · doi:10.1038/s41388-019-0948-6 · Cited by 32 · cited 1×
“Reversible tyrosine phosphorylation of DAAM1 by Src and PTPN3 regulated actin dynamics and lung cancer invasiveness [75].”
Hannon, R. A., Finkelman, R. D., Clack, G., Iacona, R. B., Rimmer, M., Gossiel, F., Baselga, J. M., & Eastell, R. (2012) · Bone · doi:10.1016/j.bone.2011.12.017 · Cited by 31 · cited 1×
“An early study designed to evaluate bone resorption markers in advanced malignancies, mainly breast and colon cancer, indicated that saracatinib was effective in inhibiting osteoclast activity and suggested the use in metastatic bone disease [158].”
Lou, L., Yu, Z., Wang, Y., Wang, S., & Zhao, Y. (2018) · Cancer Science · doi:10.1111/cas.13572 · Cited by 31
Fujisaka, Y., Onozawa, Y., Kurata, T., Yasui, H., Goto, I., Yamazaki, K., Machida, N., Watanabe, J., Shimada, H., Shi, X., et al. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9809-7 · Cited by 30
A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors
Hong, D. S., Choe, J. H., Naing, A., Wheler, J. J., Falchook, G. S., Piha-Paul, S. A., Moulder, S. L., George, G. C., Choe, J. M., Strauss, L. C., et al. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9898-3 · Cited by 30 · cited 1×
“I gemcitabine PR = 25% (pancreatic cancer) From 70 mg daily to 100 mg daily 2012 [131]”
Boateng, L. R., Cortesio, C. L., & Anna Huttenlocher, A. (2012) · Journal of Cell Science · doi:10.1242/jcs.096529 · Cited by 30 · cited 2×
“The spatiotemporal phosphorylation of cortactin and mAbp1 can regulate invadosome dynamics, with cortactin present at invadopodia during early assembly and stabilization, while mAbp1 is present at mature podosome dots [58,59].”
EGFR–c-Src-Mediated HDAC3 Phosphorylation Exacerbates Invasion of Breast Cancer Cells
Kwak, S., Seo, J., Hwang, J.-T., Sung, G., Song, J., Jeong, J., Lee, S., Yoon, H., Choi, H., & Choi, K. (2019) · Cells · doi:10.3390/cells8080930 · Cited by 30 · cited 1×
“Indeed, Src activation is a critical event in the signaling downstream EGFR during breast cancer progression, stimulating migration and invasion of surrounding tissues [64].”
Messersmith, W. A., Krishnamurthi, S., Hewes, B., Zacharchuk, C., Abbas, R., Martins, P., Dowling, E., Volkert, A., Martin, E., & DAUD, A. I. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.3552 · Cited by 30 · cited 1×
“I none SD = 12% 50 to 600 mg daily 2007 [170]”
Wang, D., Esselman, W. J., & Cole, P. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206467200 · Cited by 29 · cited 4×
“CD45, abundantly expressed in all nucleated cells of hematopoietic origin, is the most important phosphatase activating SFKs by dephosphorylation of the terminal C-tail [38].”
InfluentialBailey, K. M., Airik, M., Krook, M. A., Pedersen, E. A., & Lawlor, E. R. (2016) · Neoplasia · doi:10.1016/j.neo.2016.06.008 · Cited by 29 · cited 1×
“Specifically, Src overexpression or overactivation was associated with the aberrant formation of invadopodia, critical morphological structures employed by cancer cells to intravasate into the bloodstream and extravasate into secondary sites during the metastatic process [16,17].”
Zhao, L., Li, X., Song, N., Li, A., Hou, K., Qu, X., Che, X., & Liu, Y. (2017) · Cell Biology International · doi:10.1002/cbin.10894 · Cited by 29 · cited 1×
“The importance of SFKs in metastatic spreading is a consolidated evidence and it has been associated with different mechanisms including the promotion of tumor cell motility, epithelial-to-mesenchymal transition (EMT) as well as adaptation of resident cells in the secondary microenvironment [14,15].”
Strickler, J. H., McCall, S. J., Nixon, A. B., Brady, J. C., Pang, H., Rushing, C. N., Cohn, A. L., Starodub, A., Arrowood, C., Haley, S. T., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-0042-9 · Cited by 27 · cited 1×
“I capecitabine oxaliplatin bevacizumab PR = 10% SD = 60% 50 mg twice or 70 mg daily 2013 [150]”
Lan, T., Wang, H., Zhang, Z., Zhang, M., Qu, Y., Zhao, Z., Fan, X., Zhan, Q., Song, Y., & Yu, C. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.04.023 · Cited by 27
Role of c-Src activity in the regulation of gastric cancer cell migration
Yang, Y. S., Bai, Z., Yin, J., Wu, G., & Zhang, Z.-T. (2014) · Oncology Reports · doi:10.3892/or.2014.3188 · Cited by 26 · cited 1×
“demonstrated that the subsets of gastric cancer cells defined by a response to Src or tyrosine-protein kinase Met (MET) inhibitors were distinct, suggesting the analysis of MET amplification in the selection of patients to be treated with Src inhibitors [103,104].”
Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
Kelley, M. J., Jha, G. G., Shoemaker, D., Herndon, J. E., Gu, L., Barry, W. T., Crawford, J., & Ready, N. (2016) · Cancer Investigation · doi:10.1080/07357907.2016.1253710 · Cited by 26 · cited 1×
“Advanced Non-Small Cell Lung Cancer II none No response 70 mg twice daily 2017 [135]”
Src nuclear localization and its prognostic relevance in human osteosarcoma
Urciuoli, E., Coletta, I., Rizzuto, E., Vito, R. D., Petrini, S., D'Oria, V., Pezzullo, M., Milano, G. M., Cozza, R., Locatelli, F., et al. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26079 · Cited by 25 · cited 1×
“Recent studies have reported the presence of Src also in the nuclear compartment, and this localization seems to be relevant in the progression of some solid tumors [26,27].”
Ogunbolude, Y., Dai, C., Bagu, E. T., Goel, R. K., Miah, S., MacAusland-Berg, J., Ng, C. Y., Chibbar, R., Napper, S., Raptis, L. H., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22958 · Cited by 25 · cited 1×
“Since the involvement of different SFKs in breast cancer, different authors evaluated the effect of specific SFK inhibitors or knockdown of individual SFK members in breast cancer cells and compared the potential effects of pan-SFK and SFK-selective inhibitors on the formation of breast cancer metastasis in preclinica…”
Phase I study of dasatinib (BMS‐354825) in Japanese patients with solid tumors
Takahashi, S., Miyazaki, M., Okamoto, I., Ito, Y., Ueda, K., Seriu, T., Nakagawa, K., & Hatake, K. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.02041.x · Cited by 24 · cited 1×
“I none SD = 19% 100 mg, 150 mg, 200 mg daily 2011 [133] I none SD = 16% 35 to 160 mg twice daily 2009 [134]”
Vitale, S., Avizienyte, E., Brunton, V. G., & Frame, M. C. (2008) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2008.04.002 · Cited by 24 · cited 1×
“The involvement of Src in invadopodia formation in CRC was also associated with cancer adaptation to redox stress [85,86].”
Teng, Y., Cai, Y., Pi, W., Gao, L., & Shay, C. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0485-0 · Cited by 24
Argiris, A. E., Feinstein, T. M., Wang, L., Yang, T., Agrawal, S., Appleman, L. J., Stoller, R. G., Grandis, J. R., & Egloff, A. M. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9732-3 · Cited by 23 · cited 1×
“I cetuximab SD = 43% (better PFS in patients with low baseline TGF-α levels) 100 mg, 150 mg, 200 mg daily 2012 [132]”
Trarbach, T., Schultheis, B. S., Gauler, T. C., Schneider, V., Strumberg, D., Eberhardt, W., Scouiller, S. L., Marotti, M., Brown, K. H., & Drevs, J. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9754-x · Cited by 22 · cited 2×
“In fact, more than one-third of patients had a decrease in tumor size from baseline [162].”
Chatterji, T., Varkaris, A. S., Parikh, N. U., Song, J. H., Cheng, C.-J., Schweppe, R. E., Alexander, S., Davis, J. W., Troncoso, P., Friedl, P., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3391 · Cited by 22
Zhang, C., Miller, D. J., Guibao, C. D., Donato, D. M., Hanks, S. K., & Zheng, J. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.807271 · Cited by 21 · cited 1×
“Src substrates in FA include FAK, p130Cas, tensins, paxillin, and crk [47,48].”
Kato, S., Jardim, D. L. F., Johnson, F. M., Subbiah, V., Piha-Paul, S. A., Tsimberidou, A. M., Falchook, G. S., Karp, D. D., Zinner, R., Wheler, J. J., et al. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0513-5 · Cited by 21 · cited 1×
“Advanced solid tumors I crizotinib PR = 2% SD = 5% (mainly sarcoma and prostate cancer) 140 mg daily 2018 [130]”
c-Src is required for hypoxia-induced metastasis-associated functions in prostate cancer cells
Dai, Y., & Siemann, D. W. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s201320 · Cited by 21 · cited 1×
“In a hypoxic environment, Src activity was essential in promoting metastatic functions such as cell migration, invasion, and clonogenic survival in prostate cancer [100].”
Crosstalk between Activated and Inactivated c-Src in Hepatocellular Carcinoma
Chen, M., Chai, C., Yeh, K., Wang, S., Tsai, C.-J., Yeh, Y., & Yang, S. (2011) · Disease Markers · doi:10.1155/2011/946295 · Cited by 20
Src inhibition potentiates antitumoral effect of paclitaxel by blocking tumor-induced angiogenesis
Monache, S. D., Sanità, P., Calgani, A., Schenone, S., Botta, L., & Angelucci, A. (2014) · Experimental Cell Research · doi:10.1016/j.yexcr.2014.08.002 · Cited by 19
Self-citationLai, Y., Lin, S.-Y., Wu, Y., Chen, H., & Chen, J. J. W. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0539-3 · Cited by 19 · cited 1×
“Indeed, some authors showed how, in combination with established therapeutic agents, AC-93253 iodide, a Src-EGFR crosstalk inhibitor, blocked cancer cell growth and motility [73].”
SRC inhibition prevents P-cadherin mediated signaling and function in basal-like breast cancer cells
Ribeiro, A. S., Nobre, A. R., Mendes, N. M., Almeida, J., Vieira, A. F., Sousa, B., Carvalho, F. A., Monteiro, J., Polónia, A., Fonseca, M. B., et al. (2018) · Cell Communication and Signaling · doi:10.1186/s12964-018-0286-2 · Cited by 19 · cited 1×
“Indeed, P-cadherin overexpression is significantly associated with Src activation in breast cancer cells, a molecular event that was also validated in a large series of primary tumor samples [66].”
Olea‐Flores, M., Zuñiga‐Eulogio, M. D., Tacuba-Saavedra, A., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/739169 · Cited by 19
Cardin, D. B., Goff, L. W., Chan, E., Whisenant, J. G., Ayers, G. D., Takebe, N., Arlinghaus, L. R., Yankeelov, T. E., Berlin, J. D., & Merchant, N. B. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0519-z · Cited by 18
Crosstalk between activated and inactivated c-Src in hepatocellular carcinoma.
Chen, M., Chai, C., Yeh, K., et al. (2011) · PubMed · doi:10.3233/dma-2011-0792 · Cited by 15 · cited 1×
“The phosphorylation of Tyr530 determines conformational changes leading to intramolecular interaction with the SH2 domain and inactivating kinase activity [29].”
Moy, B., Neven, P., Lebrun, F., Bellet, M., Xu, B., Sarosiek, T., Chow, L. W., Goss, P. E., Zacharchuk, C., Leip, E. P., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0022 · Cited by 15 · cited 2×
“However, the combination with letrozole or exemestane in HR+ disease, although bosutinib demonstrated activity as single agent, resulted in unfavorable risk–benefit profile with early termination of the studies [171,172].”
Src as a Therapeutic Target in Biliary Tract Cancer
Nam, A., Kim, J., Park, J. E., Bang, J., Jin, M. H., Lee, K.-H., Kim, T., Han, S., Im, S., Kim, T., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0013 · Cited by 12 · cited 1×
“In addition, these combinations further inhibited phosphorylation of Src and its downstream molecules and decreased to a major extent EMT marker expression compared with bosutinib alone [106].”
Woodcock, V. K., Clive, S., Wilson, R. H., Coyle, V. M., Stratford, M. R. L., Folkes, L. K., Eastell, R., Barton, C. M., Jones, P. S., Kazmi-Stokes, S., et al. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.484 · Cited by 11 · cited 1×
“AZD0424 displayed no evidence of efficacy as monotherapy [174].”
Tissue specific expression of Yrk kinase: implications for differentiation and inflammation
Martins‐Green, M. M., Bixby, J. L., Yamamoto, T. S., Graf, T., & Sudol, M. (2000) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(99)00118-1 · Cited by 10 · cited 1×
“Yrk has been described only in adult chicken and it was detected in hematopoietic cells, cerebellum, spleen, lung, and skin [9,10].”
Targeting Tyrosine Kinases in Cancer: Lessons for an Effective Targeted Therapy in the Clinic
Angelucci, A. (2019) · Cancers · doi:10.3390/cancers11040490 · Cited by 10 · cited 1×
“To date tyrosine kinases (TKs) represent also the most representative class of targeted proteins in anticancer therapy [1].”
Self-citationPersonalized Cancer Therapy: YES1 Is the New Kid on the Block
Rai, K. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-2995 · Cited by 7
Predictive Biomarkers of Response to Src Inhibitors in Lung Cancer. Getting to YES1
Li, H. Y., & Carr, L. L. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201905-1092ed · Cited by 4 · cited 1×
“These data and results from other studies suggest that Yes protein expression may predict which patients with NSCLC will respond to Src inhibitors [77].”
Cited by
Exosome biogenesis: machinery, regulation, and therapeutic implications in cancer
Han, Q.-F., Li, W.-J., Hu, K.-S., Gao, J., Zhai, W.-L., Yang, J.-H., & Zhang, S.-J. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01671-0 · Cited by 678
Molecular targeted therapy for anticancer treatment
Min, H.-Y., & Lee, H.-Y. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00864-3 · Cited by 569
YAP/TAZ as master regulators in cancer: modulation, function and therapeutic approaches
Piccolo, S., Panciera, T., Contessotto, P., & Cordenonsi, M. (2022) · Nature Cancer · doi:10.1038/s43018-022-00473-z · Cited by 236
Ortiz, M. A., Mikhailova, T., Li, X., Porter, B. A., Bah, A., & Kotula, L. (2021) · Cell Communication and Signaling · doi:10.1186/s12964-021-00750-x · Cited by 154
Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma
Marin-Bejar, O., Rogiers, A., Dewaele, M., Femel, J., Karras, P., Pozniak, J., Bervoets, G., Van Raemdonck, N., Pedri, D., Swings, T., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.05.015 · Cited by 141
Metadata
- Authors
- Martellucci, S., Clementi, L., Sabetta, S., Mattei, V., Botta, L., & Angelucci, A.
- Affiliations
- University of L'Aquila (IT)
- Biomedicine and Advanced Technologies Rieti Center “Sabina Universitas”, 02100 Rieti, Italy
- Università degli Studi della Tuscia (IT)
- Corresponding author
- Angelucci, Adriano
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2020-06-02
- Volume
- 12
- Issue
- 6
- Pages
- 1448
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC7352436
- OpenAlex
- W3034094834
- Cited by
- 139
- References
- 176
- Citations by year
- 2026: 16 · 2025: 24 · 2024: 21 · 2023: 31 · 2022: 17 · 2021: 26 · 2020: 4
- FWCI
- 2.99
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi dell Aquila (submittedVersion, public-domain)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UnitusOpen (Tuscia University) (submittedVersion, public-domain)
- UnitusOpen (Tuscia University) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, cc-by)
- Funders
- Ministero dell’Istruzione, dell’Università e della Ricerca (2014-2020, DOT13SR6G7)
- Università degli Studi dell'Aquila
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- Src family kinases, tyrosine kinase inhibitors, solid tumors, metastasis, tumor progression, tumor cell migration and invasion, therapeutic target, drug resistance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.